Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

LEGN
Legend Biotech Corporation
stock NASDAQ ADR

Market Open
Jul 9, 2025 2:13:40 PM EDT
39.07USD+4.214%(+1.58)715,746
39.07Bid   39.15Ask   0.08Spread
Pre-market
Jul 9, 2025 9:25:30 AM EDT
37.93USD+1.174%(+0.44)11,686
After-hours
Jul 8, 2025 4:05:30 PM EDT
37.65USD+0.360%(+0.14)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
10:29AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022   Benzinga
08:42AM EST  Morgan Stanley Upgrades Legend Biotech to Overweight, Announces $51 Price Target   Benzinga
Jan 6, 2022
10:07AM EST  Morgan Stanley Downgrades Legend Biotech to Equal-Weight   Benzinga
Dec 21, 2021
10:14AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2021   Benzinga
05:16AM EST  Piper Sandler Initiates Coverage On Legend Biotech with Overweight Rating, Announces Price Target of $66   Benzinga
Dec 16, 2021
09:26AM EST  Legend Biotech Prices Public Offering Of 7.50 Mln At $40.00/ADS   RTTNews
09:21AM EST  Legend Biotech Prices 7.5M ADS Offering At $40/ADS   Benzinga
09:19AM EST  Legend Biotech Corporation Announces Pricing of Public Offering   Business Wire
Dec 15, 2021
08:03AM EST  The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO   Benzinga
Dec 14, 2021
04:28PM EST  Legend Biotech Reports Offering Of $300M In ADSs   Benzinga
04:28PM EST  Legend Biotech Corporation Announces Proposed Public Offering   Business Wire
Dec 13, 2021
09:48AM EST  JNJ's Janssen Posts Two Years Survival Data On BCMA Cell Therapy In Multiple Myeloma   Benzinga
09:24AM EST  Legend Biotech Says 2-Year Analysis of CARTITUDE-1 Shows Early, Durable And Deepening Responses Of Ciltacabtagene Autoleucel In Heavily Pretreated Patients With Multiple Myeloma   Benzinga
Dec 7, 2021
09:38AM EST  Legend Biotech Reports Submission Of New Drug Application To Japanese Regulatory Authority For CAR-T Therapy Cilta-Cel   Benzinga
08:30AM EST  Legend Biotech to Host Hybrid KOL Event Detailing CARTITUDE Data from the 63rd American Society of Hematology (ASH) Annual Meeting   Business Wire
Dec 6, 2021
01:02PM EST  EXCLUSIVE: Legend Biotech Spokesperson On Why Press Release From Monday Morning Was Deleted: 'There was a miscommunication and the release was issued prematurely. We intend to issue when the submission is final'   Benzinga
12:08PM EST  Legend Biotech Press Release From 8:30 a.m. EST Monday Shows Update From BusinessWire That Initial Press Release Was Deleted   Benzinga
08:35AM EST  Legend Biotech Highlights Submission Of New Drug Application To Japanese Regulatory Authority For B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor-T Cell Therapy For Treatment Of Adults With Relapsed, Refractory Multiple Myeloma   Benzinga
Nov 16, 2021
08:31AM EST  Legend Biotech Q3 EPS $(0.43) Down From $(0.25) YoY, Sales $16.90M Up From $11.75M YoY   Benzinga
Nov 2, 2021
10:54AM EDT  The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US   Benzinga
10:17AM EDT  Legend Biotech Reports Extension Of PDUFA Date For Cilta-Cell To Feb. 28, 2022   Benzinga
Oct 12, 2021
08:32AM EDT  Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $51   Benzinga
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Oct 1, 2021
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
Sep 13, 2021
08:41AM EDT  Legend Biotech Begins Phase 1 Clinical Trial In The US To Evaluate Investigational Anti-CD4 CAR-T Therapy For Relapsed Or Refractory T-Cell Lymphoma   Benzinga
Aug 23, 2021
08:11AM EDT  Legend Biotech Q2 EPS $(0.33) Up From $(0.63) YoY, Sales $20.20M Up From $11.60M YoY   Benzinga
Jul 23, 2021
07:45AM EDT  The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs   Benzinga
Jul 22, 2021
11:34AM EDT  The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO   Benzinga
Jul 21, 2021
07:52AM EDT  The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 2, 2021
07:38AM EDT  The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures   Benzinga
Jul 1, 2021
04:35PM EDT  Legend Biotech Files For Potential Mixed-Securities Shelf Offering; Size Not Disclosed   Benzinga
Jun 30, 2021
08:30AM EDT  Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors   GlobeNewswire Inc
Jun 22, 2021
08:12AM EDT  Legend Biotech Announces Establishment Of State-of-the-art Manufacturing Facility In Belgium   RTTNews
08:07AM EDT  Legend Biotech Announces New Cell Therapy Facility In Belgium   Benzinga
08:00AM EDT  Legend Biotech Announces Advancement of Global Manufacturing Infrastructure   Business Wire
Jun 1, 2021
08:25AM EDT  Legend Biotech Highlights New And Updated Data For Investigational BCMA CAR-T Ciltacabtagene Autoleucel For Treatment Of Relapsed Or Refractory Multiple Myeloma At 2021 ASCO And EHA Meetings   Benzinga
May 27, 2021
08:26AM EDT  Legend Biotech-Janssen's Multiple Myeloma Cell Therapy Under Review In US   Benzinga
08:24AM EDT  The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs   Benzinga
May 25, 2021
09:30AM EDT  Legend Biotech to Present at the Jefferies Virtual Healthcare Conference   Business Wire
May 18, 2021
08:11AM EDT  Legend Biotech Q1 EPS $(0.30) Down From $(0.22) YoY, Sales $13.70M Up From $11.50M YoY   Benzinga
Apr 30, 2021
07:21AM EDT  Legend Biotech Submits EMA For Ciltacabtagene Autoleucel For Relapsed And/or Refractory Multiple Myeloma   RTTNews
06:48AM EDT  Legend Biotech Announces Submission Of European Marketing Authorization Application For BCMA CAR-T Therapy Ciltacabtagene Autoleucel For Treatment Of Relapsed And/Or Refractory Multiple Myeloma   Benzinga
06:38AM EDT  Legend Biotech Announces Submission of European Marketing Authorisation Application for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma   Business Wire
Apr 19, 2021
10:45AM EDT  Morgan Stanley Maintains Overweight on Legend Biotech, Lowers Price Target to $50   Benzinga
Mar 18, 2021
09:53AM EDT  Legend Biotech shares were trading higher after the company reported better-than-expected Q4 EPS and sales results.   Benzinga
08:16AM EDT  The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq   Benzinga
07:13AM EDT  Legend Biotech Q4 EPS $(0.22) Beats $(0.28) Estimate, Sales $40.78M Beat $13.00M Estimate   Benzinga
07:07AM EDT  Earnings Scheduled For March 18, 2021   Benzinga
Mar 14, 2021
08:14AM EDT  Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations   Benzinga
Mar 10, 2021
04:30PM EST  Legend Biotech Announces Fourth Quarter and Full-Year 2020 Earnings Conference Call   Business Wire
Feb 19, 2021
08:10AM EST  Legend Biotech Sees FY20 Loss $(324.9M)-$(292.2M)   Benzinga
Feb 1, 2021
07:22AM EST  Legend Biotech Says BCMA CAR-T Therapy Cilta-cel Accepted For Accelerated Assessment In Europe   RTTNews
07:16AM EST  Legend Biotech Announces BCMA CAR-T Therapy Cilta-cel Accepted for Accelerated Assessment in Europe for the Treatment of Relapsed and or Refractory Multiple Myeloma   Benzinga
Dec 21, 2020
07:17AM EST  Legend Biotech Announces Initiation of Rolling Submission of Biologics License Application to U.S. FDA Seeking Approval of BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed and/or Refractory Multiple Myeloma   Benzinga
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 14, 2020
08:09AM EST  Legend Biotech Announces FDA Clearance Of The IND For LB1901, An Investigational Autologous Anti-CD4 CAR-T Therapy For Relapsed Or Refractory T-Cell Lymphoma   Benzinga
Dec 5, 2020
03:00PM EST  Legend Biotech Announces Phase 1b/2 Study Data of Cilta-cel, an Investigational BCMA CAR-T, Showing Early, Deep, and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma   Business Wire
Dec 3, 2020
08:00AM EST  Legend Biotech Announces Appointment of Dr. Patrick Casey to the Board of Directors   Business Wire
Dec 1, 2020
03:08AM EST  The lockup period of Legend Biotech Corp.(LEGN) comes to an end tomorrow, i.e., on December 2.   RTTNews
Nov 29, 2020
08:59AM EST  The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions   Benzinga
Nov 23, 2020
07:17AM EST  Legend Biotech Appoints Li Zhu To Board   RTTNews
07:00AM EST  Legend Biotech Announces New Appointment to the Board of Directors and Resignation of Dr. Fangliang Zhang   Business Wire
Nov 16, 2020
07:29AM EST  Legend Biotech Q3 Loss Per Share $0.25 Vs Loss $0.14 Last Year   RTTNews
07:07AM EST  Legend Biotech Q3 EPS $(0.25) Down From $(0.14) YoY, Sales $11.75M Down From $17.67M YoY   Benzinga
07:00AM EST  Legend Biotech Reports Third Quarter 2020 Financial Results   Business Wire
Nov 9, 2020
11:06AM EST  Legend Biotech Announces Leadership Transition   Business Wire
08:22AM EST  Legend Biotech Board Names Dr. Ying Huang As CEO   Benzinga
08:13AM EST  Legend Biotech Names Ye Wang As Chairwoman Of The Board   RTTNews
08:05AM EST  Legend Biotech Announces Leadership Transition   Business Wire
Nov 5, 2020
07:05AM EST  Legend Biotech Announces ASH 2020 Data Presentations for Ciltacabtagene Autoleucel (cilta-cel), an Investigational BCMA CAR-T Cell Therapy in Development for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)   Business Wire
Oct 8, 2020
09:41PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Legend Biotech Corporation (Legend or the Company) (NASDAQ:LEGN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Oct 7, 2020
04:00PM EDT  Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Legend Biotech Corporation (NASDAQ: LEGN) on behalf of Legend Biotech stockholders. Our investigation concerns whether Legend Biotech has violated the federal securities laws and/or engaged in other unlawful business practices.   GlobeNewswire Inc
Oct 6, 2020
06:04PM EDT  Glancy Prongay & Murray LLP (GPM) continues its investigation on behalf of Legend Biotech Corporation (Legend or the Company) (NASDAQ: LEGN) investors concerning the Companys possible violations of the federal securities laws.   GlobeNewswire Inc
08:00AM EDT  SHAREHOLDER ALERT: APLT AND LEGN Being Investigated by Block &   GlobeNewswire Inc
Oct 5, 2020
04:39PM EDT  Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Legend Biotech Corporation (NASDAQ: LEGN) resulting from allegations that Legend may have issued materially misleading business information to the investing public.   GlobeNewswire Inc
Sep 30, 2020
06:22PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Legend Biotech Corporation (Legend or the Company) (NASDAQ:LEGN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Sep 29, 2020
08:00PM EDT  Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Legend Biotech Corporation (NASDAQ: LEGN) on behalf of Legend Biotech stockholders. Our investigation concerns whether Legend Biotech has violated the federal securities laws and/or engaged in other unlawful business practices.   GlobeNewswire Inc
Sep 28, 2020
04:30PM EDT  Legend Biotech to Participate in the Jefferies Virtual Cell Therapy Summit   Business Wire
Sep 27, 2020
01:24AM EDT  Pomerantz LLP is investigating claims on behalf of investors of Legend Biotech Corporation (Legend or the Company) (NASDAQ:LEGN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Sep 25, 2020
08:00AM EDT  Investors can contact the law firm at no cost to learn more about recovering their losses   GlobeNewswire Inc
Sep 22, 2020
07:00PM EDT  Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Legend Biotech Corporation (NASDAQ: LEGN) on behalf of Legend Biotech stockholders. Our investigation concerns whether Legend Biotech has violated the federal securities laws and/or engaged in other unlawful business practices.   GlobeNewswire Inc
Sep 21, 2020
05:44PM EDT  SHAREHOLDER ALERT: Investigation of Legend Biotech Announced by Holzer & Holzer, LLC   Business Wire
03:54PM EDT  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of   PR Newswire
10:21AM EDT  Mid-Morning Market Update: Markets Open Lower; Microsoft To Acquire Game Maker ZeniMax For $7.5B   Benzinga
10:16AM EDT  Shares of Legend Biotech Corp. (LEGN) tanked 15% on Monday morning after the Chinese anti-cancer cell therapy company revealed that the Customs Anti-Smuggling Department of the China inspected offices associated with both its parent majority shareholder, GenScript Biotech Corp., and some of its own subsidiaries in the country.   RTTNews
06:35AM EDT  Legend Biotech Names Current CFO, Ying Huang, As Interim CEO   RTTNews
06:32AM EDT  Legend Biotech Names Current Chief Financial Officer, Ying Huang, As Interim CEO   Benzinga
Sep 1, 2020
04:00PM EDT  Legend Biotech to Participate in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference   Business Wire
Aug 28, 2020
04:36PM EDT  Legend Biotech Q2 Loss/share $0.63 Vs. Loss $0.14 Year Ago   RTTNews
04:35PM EDT  Legend Biotech Q2 EPS $(0.63), Sale s$11.6M, Had ~$562.4M Of Cash And Equivalents As Of Jun. 30   Benzinga
04:34PM EDT  Legend Biotech Reports Second Quarter 2020 Financial Results   Business Wire
Aug 13, 2020
08:18AM EDT  The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller   Benzinga
Aug 5, 2020
05:37PM EDT  The China Center for Drug Evaluation, National Medical Products Administration Has Recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel (cilta-cel, LCAR-B38M CAR-T Cells), an Investigational BCMA CAR-T Cell Therapy   Business Wire
Aug 2, 2020
11:02AM EDT  Legend Biotech Announces Chief Executive Officer Transition   Business Wire
10:43AM EDT  Legend Biotech Announces Preliminary Results for First Half of 2020   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC